COMP <GO>
TRLV vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TRLV 2
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $10.60 (-0.19%) • MKT CAP: $2.04B
roic
12.80%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRLV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRLV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.20% | 70.20% | -10.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 12.80% | 29.00% | -16.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.9x | 33.3x | -23.40 | TRLV | /valuation <GO> |
| Free Cash Flow Yield | 11.20% | 3.47% | +7.73 | TRLV | /fcf-yield <GO> |
| Operating Margin | 12.10% | 24.60% | -12.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -9.90% | 6.90% | -16.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -0.40% | 8.60% | -9.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.12 | 5.33 | -4.21 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.3 | 65.1 | -21.83 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.04B | $513.86B | -$511.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRLV REV | ABBV REV | TRLV GROSS % | ABBV GROSS % | TRLV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $61.16B | 60.2% | 70.2% | $228.6M | $17.82B |
| FY 2024 | $1.19B | $56.33B | 60.3% | 70.0% | $148.9M | $17.83B |
| FY 2023 | $1.13B | $54.32B | — | — | $201.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRLV // BETA —
ABBV // BETA 1.15